Want to see MBRX full AI Analyst Report?
MBRX Stock Chart & Stats
$2.12
$0.04(1.92%)
At close: 4:00 PM EDT
$2.12
$0.04(1.92%)
Day’s Range― - ―
52-Week Range$0.31 - $18.27
Previous CloseN/A
Volume44.49K
Average Volume (3M)2.74M
Market Cap
$5.44M
Enterprise Value-$0.55
Total Cash (Recent Filing)$10.32M
Total Debt (Recent Filing)$326.00K
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 19, 2026EPS Estimate
-1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.98
Shares Outstanding5,336,350
10 Day Avg. Volume1,958,319
30 Day Avg. Volume2,738,732
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$16.00Price Target Upside654.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal MIRACLE Efficacy SignalsConsistent blinded remission rates across sequential analyses and nearly completed enrollment indicate the MIRACLE pivotal study is producing reproducible efficacy signals. If unblinded Annamycin-arm superiority is confirmed, it materially strengthens regulatory and partnering prospects and de-risks long-term commercialization pathways.
Demonstrated Cardiac SafetyRobust pooled cardiac-safety data showing no anthracycline-like cardiotoxicity is a durable clinical differentiator. It allows higher cumulative dosing, expands treatable patient pools (heavily pretreated/venetoclax failures), and reduces safety-driven regulatory and commercial constraints versus traditional anthracyclines.
Strengthened IP ProtectionAdditional patent coverage in Hong Kong extends geographic exclusivity and supports a global IP fence for Annamycin. Durable patent protection through 2040 enhances long-term commercialization leverage, partner negotiation power, and potential royalty capture across important Asian markets.
Bears Say
No Product RevenueAs a clinical-stage biotech with no approved products, Moleculin has no recurring commercial cash flow. This structural absence of revenue forces reliance on financing, partnerships or milestone payments and makes internal funding of late-stage development and commercialization contingent on external capital or successful licensing.
Sustained Negative Cash FlowPersistent ~-$24M annual operating/free cash burn is a recurring structural drain that will necessitate additional financing before commercialization. Sustained negative cash flow elevates dilution risk, constrains strategic optionality, and pressures timelines for partnering or milestone-dependent funding.
Shrinking Equity/assets; Financing RiskAlthough leverage is low, a materially shrinking equity and asset base reflects cumulative losses and reduced internal capital. This longer-term erosion heightens dependence on dilutive financings or deal-making, which can limit strategic flexibility and increase shareholder dilution if development progress stalls.
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $0.31 and its highest was $18.27 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $5.44M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Aug 19, 2026 which is in 18 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on May 15, 2026. The company reported -$3.54 earnings per share for the quarter, missing the consensus estimate of -$2.333 by -$1.207.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -1.61.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 5,336,350 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$3.54 in its last earnings report, missing expectations of -$2.333. Following the earnings report the stock price went down -4.091%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company focused on developing drug candidates for the treatment of cancer and other difficult-to-treat diseases, including certain viral infections. The company’s activities center on research and development of its proprietary therapeutic technologies and product candidates and advancing them through preclinical and clinical testing, rather than commercial manufacturing and sales of approved medicines.
MBRX Stock 12 Month Forecast
Average Price Target
$16.00
▲(654.72% Upside)
Technical Analysis
Ownership Overview
1.10% Insiders
0.56% Mutual Funds
1.41% Other Institutional Investors
96.14% Public Companies and
Individual Investors